Top Defensive Stocks To Invest In Right Now: AEterna Zentaris Inc.(AEZS)
Aeterna Zentaris Inc. operates as a late-stage drug development company specialized in oncology and endocrine therapy. Its lead oncology compounds include perifosine, a PI3K/Akt pathway inhibitor that is in Phase 3 registration trial for refractory advanced colorectal cancer and multiple myeloma; and AEZS-108, a doxorubicin-targeted conjugate in Phase II for the treatment of ovarian, endometrial, castration refractory prostate, and refractory bladder cancer. The company?s lead endocrinology compound, AEZS-130, is an oral ghrelin antagonist in Phase III trial as a diagnostic test for adult growth hormone deficiency. Its pipeline also includes earlier-stage compounds, such as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma, as well as AEZS-120, an anti-cancer vaccine in pre-clinical development. The company was founded in 1991 and is headquartered in Quebec City, Canada.Advisors' Opinion:
- [By Roberto Pedone]
Aeterna Zentaris (AEZS), a specialty biopharmaceutical company, is focused on developing and commercializing novel treatments in oncology and endocrinology. This stock closed up 5% to $1.25 in Thursday's trading session.
Thursday's Range: $1.19-$1.26
52-Week Range: $0.99-$1.75
Thursday's Volume: 1.32 million
Three-Month Average Volume: 646,050
From a technical perspective, AEZS ripped sharply higher here right above its 50-day moving average of $1.17 and back above its 200-day moving average of $1.22 with strong upside volume flows. This sharp spike higher on Thursday also pushed shares of AEZS into breakout territory, since the stock took out some more near-term overhead resistance at $1.23. This move is starting to push shares of AEZS within range of triggering another big breakout trade. That trade will hit if AEZS manages to take out som! e key overhead resistance levels at $1.28 to $1.35 with high volume.
Traders should now look for long-biased trades in AEZS as long as it's trending above its 200-day at $1.22 or above Thursday's intraday low of $1.19 and then once it sustains a move or close above those breakout levels with volume that hits near or above 646,050 shares. If that breakout begins soon, then AEZS will set up to re-test or possibly take out its next major overhead resistance levels at $1.52 to $1.62.
- [By Eric Volkman]
Aeterna Zentaris (NASDAQ: AEZS ) has made a significant change in its executive suite and boardroom. David Dodd is now the company's chief executive and a member of its board of directors. He succeeds Juergen Engel. The firm did not provide the reasons for the succession.
- [By Sean Williams]
What's coming down the pipelineAvastin: Surprise: It's Roche's (NASDAQOTH: RHHBY ) wonder drug yet again! Roche's Avastin is in the process of being tested as a treatment for recurrent endometrial cancer and demonstrated promising results in a mid-stage trial according to the Journal of Clinical Oncology. Avastin, which is an angiogenesis inhibitor (a fancy way of saying it inhibits blood vessel growth), was tested on 52 evaluable patients and delivered a progression-free survival of at least six months for 21 of them. Overall median PFS was 4.2 months, and median overall survival came in at 10.5 months. Don't be surprised if Roche decides to pursue further studies of Avastin in recurrent endometrial cancer with these results. AEZS-108: Currently in late-stage development by Aeterna Zentaris (NASDAQ: AEZS ) , a holding in my own portfolio, AEZS-108 is an intravenous treatment composed of a synthe! tic pepti! de carrier and doxorubicin that targets Luteinizing Hormone Releasing Hormone-receptor expressing tumors. That series of scientific jargon simply means it targets cancer cells with minimal healthy cell death relative to the current standards of treatment. In mid-stage trials, AEZS-108 delivered an overall response rate of 30.8% and a clinical benefit rate of 74.4%. These figures were enough to get AEZS-108 a special protocol assessment (SPA), which should streamline its approval if these results stay consistent in late-stage studies.
As we saw with the current treatment options, the endometrial cancer pipeline isn't filled with a lot of choices, but they are at least more encouraging than the standard care treatments we've seen over the past three decades.
Your best investment
With very few investable options to choose from, since many of these treatments are off patent as they're decades old, I'm going to split my decision this week between Roche and Aeterna Zentaris for obvious reasons.
- [By Sean Williams]
High-risk, high-reward suggestionsExelixis (NASDAQ: EXEL ) : In November Exelixis had its first drug, known as Cometriq, approved by the Food and Drug Administration to treat metastatic medullary thyroid cancer. Although the market for this disease is pretty small -- somewhere between 500 and 700 people in the U.S. -- the near-tripling in progression-free survival, or PFS, in trials would indicate to me a strong likelihood that it could translate to success in other cancer types. In mid-stage prostate cancer trials, for instance, Cometriq was found to be particularly effective in dea! ling with! bone metastases as a second or third-line treatment. We won't get any additional data until next year on Cometriq, but positive data on the prostate cancer front could be enough to double its share price if the PFS, compared to the placebo, is notably strong. ImmunoGen (NASDAQ: IMGN ) : In February, Roche and ImmunoGen received approval for Kadcyla as a secondary treatment for HER2-positive breast cancer. This is ImmunoGen's first drug approval, and it gives the company a chance to showcase what I feel is one of the future pathways of fighting cancer -- its targeted-antibody payload, or TAP, technology. ImmunoGen's TAP technology works by attaching a toxin -- in this case Roche's Herceptin -- to an antibody, and teaching that antibody to release the to
There's an undeniably large dollar amount being pledged to cancer research, but, even if a drug gains approval, that's no guarantee that the biotech or pharmaceutical company behind that drug will be a success. Some of the biggest gains (and losses) come from taking a leap of faith based on clinical data, or the approval of one or two drugs or devices within a pipeline. After that, it's all up to the drug or devices' effectiveness, its pricing, and the success of the marketing teams promoting the drug or device. Here are a few high-risk, high-reward names you should be keeping your eye on.
source from Top Stocks For 2015:http://www.topstocksblog.com/top-defensive-stocks-to-invest-in-right-now-3.html